Plexera Bioscience Ships First Plexera(TM) K(X)5 Analyzer to Early Access Partner

Summary of 2007 Results include ISO certification update and
Status of collaborator publications
BOTHELL, Wash.--(Business Wire)--Plexera Bioscience LLC, a wholly owned subsidiary of Lumera
Corporation (NASDAQ:LMRA), announced today that it has shipped a
pre-commercial version of its novel Plexera(TM) K(X)5 Analyzer.
Plexera's first Early Access Partner is a pharmaceutical company who
will be evaluating the system as a tool for screening and
characterizing antibody libraries. As part of the early access
agreement, the customer will have a 90 day period following
installation to evaluate the platform. Pending positive evaluation
results, the customer has agreed to purchase a commercial version of
the K(X)5 Analyzer. A second early access partner is anticipated in
the second quarter.

As previously announced, Plexera intends to formally launch the
Plexera(TM) K(X)5 System at the Protein Engineering Summit (PEGS) in
early May. As part of the Early Access Program, partners will provide
application and performance data to be used in conjunction with the
launch.

"Shipment of this instrument is a key milestone in our development
path," said Dr. Timothy Londergan, President and Chief Operating
Officer of Plexera. "There are number of key innovations which bring
about significant advancements in both usability and performance and
we are excited to get these in front of the customer."

The K(X)5 Analyzer is a core component of the Plexera(TM) K(X)5
System, which provides multiplexed, label-free, kinetic analysis of
thousands of biomolecular interactions in single experiment. The
Plexera(TM) K(X)5 System is a fully integrated platform that also
includes array printing, sensor chips with specialized surface
chemistries, and sophisticated data analysis software. Numerous
innovations including a revolutionary new fluidic design which
includes a novel pump and valve system and a microfluidic cell
designed for low sample consumption have been integrated into the
Plexera(TM) K(X)5 Analyzer. Patent applications for these innovations
have been submitted.

A summary of 2007 Goals and Objectives are as follows:

Academic Beta Site Publications: A joint publication between the
Institute for Systems Biology (ISB) and the University of Washington
was submitted in November while a second manuscript from Medical
University of South Carolina is targeted for a late January
submission. Additionally, a paper co-authored by a Plexera scientist
and a University of Washington scientist was published in 2007 in the
Journal Biomaterials. An additional publication from ISB is expected
to be submitted in the first quarter of 2008.

ISO 9001-2000 Compliant: In 2007, Plexera succeeded in
implementing a Quality Management System (QMS), a necessary precursor
to ISO certification. Several significant milestones have been met
towards certification. In the fourth quarter, Plexera successfully
completed a pre-assessment audit. Following successful completion of
the certification audit scheduled to take place by the end of the
first quarter of 2008, Plexera anticipates being fully ISO 9001-2000
compliant.

Co-marketing arrangement with Printer Partners: After extensive
market and technical evaluations of commercially available microarray
printers, two commercial printers have been selected that will become
validated instrument components of the K(X)5 instrument system.
Plexera will market the K(X)5 Analyzer along with the printers as an
integrated instrument system to biomarker and antibody discovery
customers.

Array Manufacturing Partner qualified and established: Three
potential array manufacturing partners have been selected from a group
totaling eight. Final beta sampling will culminate in the first
quarter of 2008 establishing a primary and secondary source.

About Plexera Biosciences LLC

Plexera Biosciences LLC., a wholly owned subsidiary of Lumera
Corporation (NASDAQ:LMRA), is focused on providing the life sciences
market with tools, content, and methods that simply and accelerate
proteomic discovery for improved diagnostics and therapeutics. For
more information, please visit www.plexera.com.

Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors
that could cause actual results to differ materially from those
projected in the company's forward-looking statements include the
following: market acceptance of our technologies and products; our
ability to obtain financing; our financial and technical resources
relative to those of our competitors; our ability to keep up with
rapid technological change; government regulation of our technologies;
our ability to enforce our intellectual property rights and protect
our proprietary technologies; the ability to obtain additional
contract awards and to develop partnership opportunities; the timing
of commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from
time to time in the company's SEC reports, including its Annual Report
on Form 10-K, and its Quarterly Reports on Form 10-Q.

Lumera Corporation
Helene F. Jaillet, Ph.D, 425-398-6546
(Investor Relations)
or
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 (cell)
(Media)

Copyright Business Wire 2008